Inhibitors of SGLT1 and SGLT2 represent novel therapeutic agents for type 2 diabetes mellitus (T2D), with SGLT2 inhibitors like dapagliflozin, canagliflozin, and empagliflozin now widely used in clinical practice due to their durable glucose lowering, fewer adverse effects, and additional cardiorenal benefits (Cui et al., 2023; Scheen, 2020). The gene discussed is SLC5A1; the disease is type 2 diabetes mellitus.